Consensus ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:52:56 2024-12-13 pm EST			5-day change	1st Jan Change
208.68 ^USD	-1.01%		-4.11%	-26.33%

Dec. 02	Nephron Upgrades ICON to Buy, Price Target is $280	MT
Nov. 25	Fed minutes and inflation data set to stir Thanksgiving week

Evolution of the Average Target: ICON Public Limited Company

Evolution of the Target Price: ICON Public Limited Company

Changes in Analyst Recommendations: ICON Public Limited Company

f9dfe3eee57666.TT_zDiNW15gRBEd2LTEJgkZ5uix0ktwcjOWLUrnFwzY.KnK1YHU84chyaCA6antgtzID6B0NprJN3r3NIfH2qVojV6dHcT6m3V9SJA~c9ff6e9ad9b186d06a1cf3d595ec907a

Analysts' recommendations: ICON Public Limited Company

Nephron Upgrades ICON to Buy, Price Target is $280	Dec. 02	MT
Analyst recommendations: Five Below, Robinhood, Snowflake, Block, Ge Vernova...	Nov. 25
UBS Adjusts Price Target on ICON to $290 From $380, Maintains Buy Rating	Oct. 25	MT
Baird Downgrades ICON to Neutral From Outperform, Price Target is $340	Oct. 24	MT
Analyst recommendations: P&G, Enphase, AT&T, Deckers Outdoor, ServiceNow...	Oct. 24
Deutsche Bank Adjusts ICON Price Target to $360 From $370, Maintains Buy Rating	Oct. 16	MT
Leerink Initiates ICON at Outperform With $379 Price Target	Sep. 18	MT
Leerink Partners Initiates ICON at Outperform	Sep. 18	MT
Truist Adjusts Price Target on ICON to $383 From $367, Maintains Buy Rating	Jul. 26	MT
Baird Adjusts Price Target on ICON to $367 From $363, Maintains Outperform Rating	May. 31	MT
UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating	Apr. 26	MT
Evercore ISI Adjusts Price Target on ICON to $350 From $325, Keeps Outperform Rating	Feb. 23	MT
UBS Adjusts ICON Price Target to $368 From $295, Maintains Buy Rating	Feb. 23	MT
Mizuho Securities Ups Price Target on ICON to $346 From $315, Keeps Buy Rating	Feb. 23	MT
Barclays Adjusts Price Target on ICON to $355 From $325, Maintains Overweight Rating	Feb. 23	MT
Truist Securities Raises Price Target on ICON to $367 From $357, Maintains Buy Rating	Feb. 23	MT
Deutsche Bank Raises ICON Price Target to $345 From $320, Maintains Buy Rating	Feb. 22	MT
Analyst recommendations: Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21
Barclays Adjusts Price Target on ICON to $325 From $280, Maintains Overweight Rating	Jan. 25	MT
Truist Securities Starts Coverage on ICON with Buy Rating, $357 Price Target	Dec. 15	MT
Citigroup Adjusts ICON Price Target to $315 From $300, Maintains Buy Rating	Dec. 11	MT
Analyst recommendations: Adobe, AMD, Apple, Costco, HP, Snap...	Dec. 11
Analyst recommendations: Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...	Dec. 04
Deutsche Bank Raises ICON Price Target to $320 From $295, Maintains Buy Rating	Nov. 30	MT
Analyst recommendations: Blackrock, Costco, Dollar Tree, Duke Energy, Snowflake...	Nov. 30

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	ICON PUBLIC LIMITED COMPANY					+30.95%
	LONZA GROUP AG					+15.69%
	IQVIA HOLDINGS INC.					+24.96%
	CELLTRION, INC.					+33.56%
	MODERNA, INC.					+73.25%
	UNITED THERAPEUTICS CORPORATION					+5.70%
	BIO-TECHNE CORPORATION					+11.17%
	MEDPACE HOLDINGS, INC.					+0.14%
	QIAGEN N.V.					+11.54%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+11.33%
	Average					+21.83%
	Weighted average by Cap.					+23.45%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

210.81USD

Average target price

276.06USD

Spread / Average Target

+30.95%

High Price Target

300.00USD

Spread / Highest target

+42.31%

Low Price Target

232.00USD

Spread / Lowest Target

+10.05%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Nephron Research
UBS
Baird
Deutsche Bank Securities
Leerink Partners
Evercore ISI
Mizuho Securities
Barclays
Truist Securities
Citigroup
Wells Fargo Securities
JPMorgan Chase
Morningstar
Guggenheim
BofA Securities
Credit Suisse
Jefferies & Co.
Goldman Sachs